Upstream Bio (UPB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
The annual meeting will be held virtually on June 9, 2026, with shareholders able to vote online or by proxy.
Shareholders will vote on electing two class II directors and ratifying the appointment of PwC as the independent auditor for 2026.
The company uses online proxy materials to reduce costs and environmental impact.
Only common stockholders as of April 13, 2026, are entitled to vote; each share equals one vote.
Voting matters and shareholder proposals
Proposal 1: Elect two class II directors (H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D.) for three-year terms expiring in 2029.
Proposal 2: Ratify PwC as independent registered public accounting firm for fiscal year ending December 31, 2026.
Shareholders may submit proposals for the 2027 meeting by December 17, 2026, or nominate directors with advance notice.
Board of directors and corporate governance
The board is divided into three classes with staggered three-year terms; currently seven members.
All directors except the CEO are considered independent under Nasdaq and SEC rules.
Board committees include audit, compensation, and nominating/governance, each with defined charters and responsibilities.
The chairperson and CEO roles are separated to enhance governance.
Directors are expected to attend at least 75% of meetings and the annual meeting.
Latest events from Upstream Bio
- Verekitug cut severe asthma exacerbations by 56% and improved lung function with strong safety.UPB
Study result20 Apr 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.UPB
Proxy filing16 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation8 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation26 Mar 2026 - Strong Phase 2 results and robust cash position support a high-dose quarterly Phase 3 strategy.UPB
Q4 202526 Mar 2026 - Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing.UPB
Leerink Global Healthcare Conference 20269 Mar 2026 - Verekitug's phase II data support robust efficacy and safety, with phase III trials set to launch soon.UPB
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Verekitug shows robust efficacy and safety, with pivotal asthma data expected in 2026.UPB
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Verekitug delivers robust efficacy and safety with extended dosing, targeting major respiratory markets.UPB
Corporate presentation12 Jan 2026